We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received ???1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were ???41,417 (???539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy. ?? 2013 Elsevier Ltd
Many cost analyses of stem-cell transplantations are available, which is in sharp contrast to the le...
No recent full-text-based systematic review has been published to examine economic evidence around a...
Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical o...
We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chro...
textabstractDuring the last decade the management of CLL was subject to progressive changes in diagn...
Objectives: Treatment of chronic lymphocytic leukemia (CLL) is currently undergoing dramatic changes...
Background: Obinutuzumab combined with chlorambucil (GClb) has shown to be superior to rituximab com...
AbstractBackgroundObinutuzumab combined with chlorambucil (GClb) has shown to be superior to rituxim...
Purpose Oral targeted therapies represent a significant advance for the treatment of patients with c...
BACKGROUND AND OBJECTIVES: Few economic data exist on the treatment of indolent non-Hodgkin's lympho...
AbstractObjectiveThe aim of this study was to identify, from a health care perspective, the cost of ...
International audienceBackground: Lymphomas are costly diseases that suffer from a lack of detailed ...
In a retrospective study we calculated the costs of introducing autologous BMT in the treatment of p...
In this article, we carry out an overview on the management options available for chronic lymphocyti...
Background and Objectives. We assessed direct health care costs associated with the most commonly pr...
Many cost analyses of stem-cell transplantations are available, which is in sharp contrast to the le...
No recent full-text-based systematic review has been published to examine economic evidence around a...
Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical o...
We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chro...
textabstractDuring the last decade the management of CLL was subject to progressive changes in diagn...
Objectives: Treatment of chronic lymphocytic leukemia (CLL) is currently undergoing dramatic changes...
Background: Obinutuzumab combined with chlorambucil (GClb) has shown to be superior to rituximab com...
AbstractBackgroundObinutuzumab combined with chlorambucil (GClb) has shown to be superior to rituxim...
Purpose Oral targeted therapies represent a significant advance for the treatment of patients with c...
BACKGROUND AND OBJECTIVES: Few economic data exist on the treatment of indolent non-Hodgkin's lympho...
AbstractObjectiveThe aim of this study was to identify, from a health care perspective, the cost of ...
International audienceBackground: Lymphomas are costly diseases that suffer from a lack of detailed ...
In a retrospective study we calculated the costs of introducing autologous BMT in the treatment of p...
In this article, we carry out an overview on the management options available for chronic lymphocyti...
Background and Objectives. We assessed direct health care costs associated with the most commonly pr...
Many cost analyses of stem-cell transplantations are available, which is in sharp contrast to the le...
No recent full-text-based systematic review has been published to examine economic evidence around a...
Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical o...